Furthermore, the relationship between risk score and tumor immunotherapy was explored and the results show that risk score is negatively correlated with the expression level of PD-1, which may be due to the immunosuppressive microenvironment and is consistent with the modest curative effect of anti-PD-1 drugs in pancreatic cancer [27]. This evidence concerns the gene PDCD1 and familial pancreatic carcinoma.